by Raynovich Rod | Apr 15, 2014 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Update at Close 4/15….. Late Day Reversal To Green The NASDAQ Composite began a rally at 1P EDT and never stopped , moving up 62 points to close at 4034. Biotech ETFs followed step by step to end up in the green after a severe daily decline. The IBB ($217.6) ended up...
by Raynovich Rod | Apr 3, 2014 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Update 4/4/14 Breach of Technicals-A Tad Below Early February Support Glut of Biotech IPOs Causing Indigestion? Momentum Days Are So Over NASDAQ Down 1.34% The volatile and speculative SPDR S&P Biotech XBI hit $136 in early trading down 2.28%.After a brief rally...
by Raynovich Rod | Apr 1, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Rayno Biopharmaceutical Portfolio 3/31/14 Most of our biotech picks did well in a tough quarter that went through a severe correction in early February and again in late March. Many small and mid-cap momentum stocks were crushed but indices (FBT,IBB) overall held the...
by Raynovich Rod | Mar 31, 2014 | Biopharmaceuticals
Large Cap Biopharmaceutical Growth Stocks With the MoMo days over the next earnings cycle (Q1,Q2 2014) should give us better clarity on winners for 2014.On the last day of March all of these large caps rallied after a severe one week correction from 3/21-28. Watch...
by Raynovich Rod | Mar 26, 2014 | Biopharmaceuticals
(See Full Article in Seeking Alpha 3/26) Biopharmaceutical Downdraft 15% From February Highs (IBB$239) Large Cap Biopharmaceutical Stocks Are Core Holdings: ABBV, AMGN, GILD The biotech frenzy of MoMo investing is over so it is time to invest longer term with quality...
by Raynovich Rod | Mar 21, 2014 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Biotech Stocks Will Need To Rebuild Confidence With Momentum Gone Damage on Friday 3/21 was considerable but most indices/ETFs are above 2014 Feb 6 low: FBIOX ($206.4) Up 13.6% YTD, FEB 5 low $196.24 IBB ($246) Up 8.35% YTD, FEB 6 low $237. PBE ($43.33) Up 16.94%...
by Raynovich Rod | Mar 18, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Update 3/19/14 Trading is mixed near flat line. Cramer to pump Seattle Genetics (SGEN ($53.51 flat) today; on our focus list since’09 at $9.50. Exact Sciences (EXAS) up ~3% on data release for Cologuard compared to FIT. Sensitivity of 92% with colorectal cancer...
by Raynovich Rod | Mar 17, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Life Science ETF's and Mutual Funds
XBI Outperforms FBIOX YTD Many biotech stocks sold off today despite a strong market on weak volume as industrials and tech were up about 1.4%. Watch the ETFs compared to Fidelity FBIOX because the sector is more volatile this month. Here is a chart comparing three...
by Raynovich Rod | Feb 27, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Clinical Diagnostics and Tools
Rayno Life Science Movers -Diagnostics Review Next Week Despite some choppiness in biotech trading this week many of our stocks did well. I won’t go into some of the unusual volatility in other small and mid-caps lately but that is part of the reason for my...
by Raynovich Rod | Feb 25, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech May Be A Bubble-But What to Do? The blogosphere is trying to temper bullish sentiment with a lot of “bubble “talk even though the cable channels are still pumping biotech. If you have been around biotech for 25 years especially during the last...
